Mental Health Services Research

, Volume 7, Issue 2, pp 123–134 | Cite as

The Effects of Race and Criminal Justice Involvement on Access to Atypical Antipsychotic Medications Among Persons with Schizophrenia

  • Richard A. Van DornEmail author
  • Jeffrey W. Swanson
  • Marvin S. Swartz
  • Eric B. Elbogen


This study examined the impact of race and arrest history on the likelihood of being prescribed, and maintaining an atypical antipsychotic prescription for 90 or more days among patients with schizophrenia in the community. Participants were 224 adults with schizophrenia-spectrum disorders receiving services in public-sector mental health systems in North Carolina. The data used for this report were from a subsample of a larger group of participants being followed in an observational study and consisted of individuals who were prescribed either an atypical or conventional antipsychotic medication for 90 or more days. The purpose of the analyses presented here was to investigate differences in the likelihood of being prescribed an atypical antipsychotic by demographic and other characteristics. Logistic regression analysis indicated that African American patients were significantly less likely to receive atypical antipsychotics than their white counterparts, even when controlling for key clinical and demographic variables. However, white patients with a history of arrest were no more likely than black patients to receive atypical antipsychotics; that is, minority racial status and criminal involvement each functioned to limit patients’ access to the novel medications. Implications for equal access to mental health services, in this case, effective psychopharmacologic treatment, are discussed.


race arrest atypical schizophrenia access 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adebimpe, V. R. (1994). Race, racism, and epidemiological surveys. Hospital and Community Psychiatry, 45, 27–31.PubMedGoogle Scholar
  2. Alegria, M., Bijl, R. V., Lin, E., Walters, E. E., & Kessler, R. C. (2000). Income differences in persons seeking outpatient treatment for mental disorders: A comparison of the United States with Ontario and The Netherlands. Archives of General Psychiatry, 57(4), 383–391.CrossRefPubMedGoogle Scholar
  3. Alegria, M., Canino, G., Rios, R., Vera, M., Calderon, J., Rusch, D., et al. (2002). Inequalities in use of specialty mental health services among Latinos, African Americans, and non-Latino whites. Psychiatric Services, 53(12), 1547–1555.CrossRefPubMedGoogle Scholar
  4. Austin, R. L., & Allen, M. D. (2000). Racial disparity in arrest rates as an explanation of racial disparity in commitment to Pennsylvania’s prisons. Journal of Research in Crime and Delinquency, 37(2), 200–220.Google Scholar
  5. Baillargeon, J., & Contreras, S. A. (2001). Antipsychotic prescribing patterns in the Texas prison system. Journal of the American Academy of Psychiatry and the Law, 29(1), 48–53.PubMedGoogle Scholar
  6. Buchanan, R. W. (1995). Clozapine: Efficacy and safety. Schizophrenia Bulletin, 21(4), 579–591.PubMedGoogle Scholar
  7. Casey, D. E. (1997). The relationship of pharmacology to side effects. Journal of Clinical Psychiatry, 58(Suppl. 10), 55–62.PubMedGoogle Scholar
  8. Chow, J. C. -C., Jaffee, K., & Snowden, L. (2003). Racial/ethnic disparities in the use of mental health services in poverty areas. American Journal of Public Health, 93(5), 792–797.PubMedGoogle Scholar
  9. Citrome, L., Levine, J., & Allingham, B. (1996). Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacology Bulletin, 32(3), 321–326.PubMedGoogle Scholar
  10. Council of State Governments. (2002). Criminal justice/mental health consensus project. Lexington, KY: Council of State Governments.Google Scholar
  11. Diala, C., Muntaner, C., Walrath, C., Nickerson, K. J., LaVeist, T. A., & Leaf, P. J. (2000). Racial differences in attitudes toward professional mental health care and in the use of services. American Journal of Orthopsychiatry, 70(4), 455–464.PubMedGoogle Scholar
  12. Dimova, A. (2003). The range of therapeutic efficacy of atypical antipsychotics: A critical evaluation. Medical Hypotheses, 61(2), 259–264.CrossRefPubMedGoogle Scholar
  13. Ditton, P. M. (1999). Mental health and treatment of inmates and probationers (No. NCJ 174463). Washington, DC: U.S. Department of Justice, Bureau of Justice Statistics.Google Scholar
  14. Dixon, L., Green-Paden, L., Delahanty, J., Lucksted, A., Postrado, L., & Hall, J. (2001). Variables associated with disparities in treatment of patients with schizophrenia and comorbid mood and anxiety disorders. Psychiatric Services, 52(9), 1216– 1222.CrossRefPubMedGoogle Scholar
  15. Drake, R. E., Mueser, K. T., & McHugo, G. J. (1996). Clinical rating scales: Alcohol Use Scale (AUS), Drug Use Scale (DUS), and Substance Abuse Treatment Scale (SATS). In L. I. Sederer & B. Dickey (Eds.), Outcomes assessment in clinical practice (pp. 113–116). Baltimore, MD: Williams & Wilkins.Google Scholar
  16. Edens, J. F., Peters, R. H., & Hills, H. A. (1997). Treating prison inmates with co-occurring disorders: An integrative review of existing programs. Behavioral Sciences and the Law, 15(4), 439–457.CrossRefPubMedGoogle Scholar
  17. Eli Lilly & Company. (1999). SCAP health questionnaire. Indianapolis, IN.Google Scholar
  18. Endicott, J., Spitzer, R., Fleiss, J., & Cohen, J. (1976). The global assessment scale: A procedure for measuring overall severity of psychiatric disturbances. Archives of General Psychiatry, 33, 766–771.PubMedGoogle Scholar
  19. Fazela, S., & Danesh, J. (2002). Serious mental disorder in 23000 prisoners: A systematic review of 62 surveys. The Lancet, 359(9306), 545–550.CrossRefGoogle Scholar
  20. Feder, L. (1991). A comparison of the community adjustment of mentally ill offenders with those from the general prison population: An 18-month follow-up. Law and Human Behavior, 15, 477–493.Google Scholar
  21. Feder, L. (1994). Psychiatric hospitalization history and parole decisions. Law and Human Behavior, 18, 395–410.CrossRefGoogle Scholar
  22. Frankle, W. G., Shera, D., Berger-Hershkowitz, H., Evins, A. E., Connolly, C., Goff, D. C., et al. (2001). Clozapine-associated reduction in arrest rates of psychotic patients with criminal histories. American Journal of Psychiatry, 158(2), 270– 274.CrossRefPubMedGoogle Scholar
  23. Garb, H. N. (1997). Race bias, social class bias, and gender bias in clinical judgment. Clinical Psychology-Science and Practice, 4(2), 99–120.Google Scholar
  24. Glassman, A. H., & Bigger, J. T. (2001). Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. American Journal of Psychiatry, 158(11), 1774–1782.CrossRefPubMedGoogle Scholar
  25. Hale, A. S. (1998). A review of the safety and tolerability of sertindole. International Clinical Psychopharmacology, 13(Suppl. 3), S65–S70.PubMedGoogle Scholar
  26. Hamilton, S. H., Revicki, D. A., Genduso, L. A., & Beasley, C. M., Jr. (1998). Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology, 18(1), 41–49.CrossRefPubMedGoogle Scholar
  27. Hammett, T. M., Roberts, C., & Kennedy, S. (2001). Health-related issues in prisoner reentry. Crime and Delinquency, 47(3), 390–409.Google Scholar
  28. Haywood, T. W., Kravitz, H. M., Grossman, L. S., Cavanaugh, J. L., Davis, J. M., & Lewis, D. A. (1995). Predicting the revolving-door phenomenon among patients with schizophrenic, schizoaffective, and affective-disorders. American Journal of Psychiatry, 152(6), 856–861.PubMedGoogle Scholar
  29. Henderson, D. C. (2002). Atypical antipsychotic-induced diabetes mellitus: How strong is the evidence? CNS Drugs, 16(2), 77–89.PubMedGoogle Scholar
  30. Hoptman, M. J., Yates, K. F., Patalinjug, M. B., Wack, R. C., & Convit, A. (1999). Clinical prediction of assaultive behavior among male psychiatric patients at a maximum-security forensic facility. Psychiatric Services, 50(11), 1461–1466.PubMedGoogle Scholar
  31. Horner, R. D., Swanson, J. W., Bosworth, H. B., & Matchar, D. B. (2003). Effects of race and poverty on the process and outcome of inpatient rehabilitation services among stroke patients. Stroke, 34, 1027–1031.CrossRefPubMedGoogle Scholar
  32. Jacoby, J. E., & Kozie-Peak, B. (1997). The benefits of social support for mentally ill offenders: Prison to community transitions. Behavioral Sciences and the Law, 15, 483–501.CrossRefPubMedGoogle Scholar
  33. Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45(9), 789–796.PubMedGoogle Scholar
  34. Keith, S. J., Regier, D. A., & Rae, D. S. (1991). Schizophrenic disorders. In L. N. Robins & D. A. Regier (Eds.), Psychiatric disorders in the America: The Epidemiologic Catchment Area Study (pp. 33–52). New York: Free Press.Google Scholar
  35. Kendler, K. S., Gallagher, T. J., Abelson, J. M., & Kessler, R. C. (1996). Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample: The National Comorbidity Survey. Archives of General Psychiatry, 53, 1022–1031.PubMedGoogle Scholar
  36. Koro, C. E., Fedder, D. O., L’Italien, G., Weiss, S., Magder, L. S., Kreyenbuhl, J., et al. (2002a). An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Archives of General Psychiatry, 59(11), 1021–1026.CrossRefGoogle Scholar
  37. Koro, C. E., Fedder, D. O., L’Italien, G. J., Weiss, S. S., Magder, L. S., Kreyenbuhl, J., et al. (2002b). Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: Population based nested case–control study. British Medical Journal, 325(7358), 243–245.Google Scholar
  38. Kressin, N. R., & Petersen, L. A. (2001). Racial differences in the use of invasive cardiovascular procedures: Review of the literature and prescription for future research. Annals of Internal Medicine, 135(5), 352–366.PubMedGoogle Scholar
  39. Kuno, E., & Rothbard, A. B. (2002). Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. American Journal of Psychiatry, 159(4), 567–572.CrossRefPubMedGoogle Scholar
  40. Lawson, W. B. (1996). Clinical issues in the pharmacotherapy of African Americans. Psychopharmacology Bulletin, 32, 275–279.PubMedGoogle Scholar
  41. Lehman, A. F., & Steinwachs, D. M. (1998). Patterns of usual care for schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) client survey. Schizophrenia Bulletin, 24(1), 11–20.PubMedGoogle Scholar
  42. Lieberman, J. A. (1996). Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis. Journal of Clinical Psychiatry, 57(Suppl. 11), 68–71.PubMedGoogle Scholar
  43. Mark, T. L., Dirani, R., Slade, E., & Russo, P. A. (2002). Access to new medications to treat schizophrenia. Journal of Behavioral Health Services and Research, 29(1), 15–29.Google Scholar
  44. Mark, T. L., Palmer, L. A., Russo, P. A., & Vasey, J. (2003). Examination of treatment pattern differences by race. Mental Health Services Research, 5(4), 241–250.CrossRefPubMedGoogle Scholar
  45. Moore, N. A. (1999). Behavioural pharmacology of the new generation of antipsychotic agents. British Journal of Psychiatry, 174(Suppl. 38), 5–11.Google Scholar
  46. Morgan, D. W., Edwards, A. C., & Faulkner, L. R. (1993). The adaptation to prison by individuals with schizophrenia. Bulletin of the American Academy of Psychiatry and the Law, 21(4), 427–433.PubMedGoogle Scholar
  47. Morrissey, J. P., Swanson, J. W., Goldstrom, I., & Manderscheid, R. W. (1993). Overview of mental health services provided by state adult correctional facilities: United States, 1988. Mental Health Statistical Note, 207, 1–13.PubMedGoogle Scholar
  48. Neighbors, H. W., Jackson, J. S., Campbell, L., & Williams, D. (1989). The influence of racial factors on psychiatric diagnosis: A review and suggestions for research. Community Mental Health Journal, 25(4), 301–311.CrossRefPubMedGoogle Scholar
  49. Nelson, K., Norris, K., & Mangione, C. M. (2002). Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: Data from the Third National Health and Nutrition Examination Survey. Archives of Internal Medicine, 162(8), 929–935.CrossRefPubMedGoogle Scholar
  50. Padgett, D., Patrick, C., Burns, B., & Schlesinger, H. (1994). Ethnicity and the use of outpatient mental health services in a national insured population. American Journal of Public Health, 84(2), 222–226.PubMedGoogle Scholar
  51. Pescosolido, B. A., Monahan, J., Link, B. G., Stueve, A., & Kikuzawa, S. (1999). The public’s view of the competence, dangerousness, and need for legal coercion of persons with mental health problems. American Journal of Public Health, 89(9), 1339–1345.PubMedGoogle Scholar
  52. Potvin, S., Stip, E., & Roy, J. Y. (2003). Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: Towards testable hypotheses. International Clinical Psychopharmacology, 18(3), 121–132.CrossRefPubMedGoogle Scholar
  53. Price, N., Glazer, W., & Morgenstern, H. (1985). Demographic predictors of the use of injectable versus oral antipsychotic medications in outpatients. American Journal of Psychiatry, 142(12), 1491–1492.PubMedGoogle Scholar
  54. Revicki, D. A., Genduso, L. A., Hamilton, S. H., Ganoczy, D., & Beasley, C. M., Jr. (1999). Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial. Quality of Life Research, 8(5), 417–426.CrossRefPubMedGoogle Scholar
  55. Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., et al. (1997). A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. New England Journal of Medicine, 337(12), 809–815.CrossRefPubMedGoogle Scholar
  56. Sampson, R. J., & Lauritsen, J. L. (1997). Racial and ethnic disparities in crime and criminal justice in the United States. Ethnicity, Crime, and Immigration, 21, 311–374.Google Scholar
  57. Segal, S. P., Bola, J. R., & Watson, M. A. (1996). Race, quality of care and antipsychotic prescribing practices in psychiatric emergency services. Psychiatric Services, 47(3), 282–286.PubMedGoogle Scholar
  58. Sheitman, B. B., Lee, H., Strauss, R., & Lieberman, J. A. (1997). The evaluation and treatment of first-episode psychosis. Schizophrenia Bulletin, 23(4), 653–661.PubMedGoogle Scholar
  59. Shore, D. (1998). Editorial: Recent developments in atypical antipsychotic medications. Schizophrenia Bulletin, 24(1), 33.PubMedGoogle Scholar
  60. Smelson, D. A., Losonczy, M. F., Davis, C. W., Kaune, M., Williams, J., & Ziedonis, D. (2002). Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Canadian Journal of Psychiatry, 47(7), 671–675.Google Scholar
  61. Steadman, H. J., Fabisiak, S., Dvoskin, J., & Holohean, E. J., Jr. (1987). A survey of mental disability among state prison inmates. Hospital and Community Psychiatry, 38(10), 1086– 1090.PubMedGoogle Scholar
  62. Swanson, J. W., Borum, R., Swartz, M. S., & Hiday, V. (1999). Violent behavior preceding hospitalization among persons with severe mental illness. Law and Human Behavior, 23(2), 185–204.CrossRefPubMedGoogle Scholar
  63. Swanson, J. W., Estroff, S., Swartz, M. S., Borum, R., Lachicotte, W., Zimmer, C., et al. (1997). Violence and severe mental disorder in clinical and community populations: The effects of psychotic symptoms, comorbidity, and lack of treatment. Psychiatry, 60(1), 1–22.PubMedGoogle Scholar
  64. Swanson, J. W. (2001). Correctional mental health in North Carolina: An expensive non-solution. The Journal of Common Sense, 6(3).Google Scholar
  65. Swanson, J. W., Swartz, M. S., Borum, R., Hiday, V. A., Wagner, H. R., & Burns, B. J. (2000). Involuntary out-patient commitment and reduction of violent behaviour in persons with severe mental illness. British Journal of Psychiatry, 176, 324–331.CrossRefPubMedGoogle Scholar
  66. Swanson, J. W., Swartz, M. S., & Elbogen, E. B. (2004). Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophrenia Bulletin, 30(1), 3–20.PubMedGoogle Scholar
  67. Takeuchi, D. T., & Williams, D. R. (2003). Race, ethnicity and mental health: Introduction to the special issue. Journal of Health and Social Behavior, 44(3), 233–236.Google Scholar
  68. Teplin, L. A. (1990a). Detecting disorder: The treatment of mental illness among jail detainees. Journal of Consulting and Clinical Psychology, 58(2), 233–236.CrossRefGoogle Scholar
  69. Teplin, L. A. (1990b). The prevalence of severe mental disorder among male urban jail detainees: Comparison with the Epidemiologic Catchment Area Program. American Journal of Public Health, 80(6), 663–669.Google Scholar
  70. Teplin, L. A., Abram, K. M., & McClelland, G. M. (1997). Mentally disordered women in jail: Who receives services? American Journal of Public Health, 87(4), 604– 609.PubMedGoogle Scholar
  71. Tollefson, G. D., Beasley, C. M., Jr., Tran, P. V., Street, J. S., Krueger, J. A., Tamura, R. N., et al. (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. American Journal of Psychiatry, 154(4), 457–465.PubMedGoogle Scholar
  72. Turner, B. J., Cunningham, W. E., Duan, N., Andersen, R. M., Shapiro, M. F., Bozzette, S. A., et al. (2000). Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus. Archives of Internal Medicine, 160(17), 2614– 2622.CrossRefPubMedGoogle Scholar
  73. Veysey, B. M. (1994). Challenges for the future. Washington, DC: U.S. Department of Justice, National Institute of Corrections.Google Scholar
  74. Walmsley, R. (2000). World prison population list (No. 88). London: Home Office Research.Google Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Richard A. Van Dorn
    • 1
    • 2
    Email author
  • Jeffrey W. Swanson
    • 1
  • Marvin S. Swartz
    • 1
  • Eric B. Elbogen
    • 1
  1. 1.Services Effectiveness Research Program, Department of Psychiatry & Behavioral SciencesDuke University Medical CenterDurham
  2. 2.Duke University Medical CenterDurham

Personalised recommendations